Highly Active Antiretroviral Therapy and Anti-tuberculosis Drug Interactions with Associated Clinical Implications: A Review
| Autor: | Nebere Sn, Karanja Jk, Achieng Ho, Kiboi Ng |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Drug medicine.medical_specialty Tuberculosis Nevirapine business.industry Opportunistic infection media_common.quotation_subject medicine.medical_treatment 030106 microbiology Immunosuppression Disease Pharmacology medicine.disease 03 medical and health sciences Therapeutic approach Acquired immunodeficiency syndrome (AIDS) Medicine business Intensive care medicine media_common medicine.drug |
| Zdroj: | Journal of Drug Metabolism & Toxicology. 7 |
| ISSN: | 2157-7609 |
| DOI: | 10.4172/2157-7609.1000207 |
| Popis: | Tuberculosis is the most common opportunistic infection associated with HIV/AIDS, and remains a disease of global significance. Co-infection with HIV complicates proper TB diagnosis and therapeutic outcomes. Profound immunosuppression characterizes HIV/TB co-infection prompting early initiation of HAART during TB treatment. Effective management of the co-infection requires concomitant administration of ART and anti-tuberculosis drugs; however, this therapeutic approach has had its fair share of challenges including: overlapping drug toxicities, drugdrug interactions and immune reconstitution reactions. For instance, combination of nevirapine-based ART and rifampicin-based TB treatment is reported to cause hepatotoxicity in healthy volunteers. As such, this review compiles information from multiple studies describing drug interactions associated with co-treatments, with a view to improving management of these co-morbidities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|